z-logo
open-access-imgOpen Access
Mycobacterium tuberculosisMicrobiologic and Clinical Treatment Outcomes in a Randomized Trial of Immediate versus CD4+‐Initiated Antiretroviral Therapy in HIV‐Infected Adults with a High CD4+Cell Count
Author(s) -
Gabriel Chamie,
Edwin D. Charlebois,
Padmini Srikantiah,
Maria Walusimbi-Nanteza,
Roy D. Mugerwa,
Harriet MayanjaKizza,
Alphonse Okwera,
Christopher C. Whalen,
Diane V. Havlir
Publication year - 2010
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/654799
Subject(s) - medicine , tuberculosis , sputum , mycobacterium tuberculosis , randomized controlled trial , directly observed therapy , sida , clinical trial , antiretroviral therapy , human immunodeficiency virus (hiv) , immunology , viral disease , viral load , pathology
In a prospective randomized, controlled trial in Uganda comparing the efficacy of antiretroviral therapy during tuberculosis therapy with the efficacy of tuberculosis therapy alone in HIV-infected patients with tuberculosis who have a CD4(+) cell count >350 cells/microL, it was found that antiretroviral therapy did not accelerate microbiologic, radiographic, or clinical responses to tuberculosis therapy: 18% of participants had sputum smears positive for Mycobacterium tuberculosis after 5 months of tuberculosis therapy, despite having had negative culture results. Trial registration. ClinicalTrials.gov identifier: NCT00078247 .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom